A device and method for detecting concentration of anti-tumor drug metabolites in blood

Abstract

The present invention discloses a device and method for detecting the concentration of anti-tumor drug metabolites in blood, which belongs to the field of drug detection, and comprises a housing, wherein a buffer cartridge is installed on the upper end surface of the housing, an antibody liquid cartridge is installed on the upper surface of the housing near the buffer cartridge, a blood measuring cartridge is installed on the upper surface of the housing near the buffer cartridge, and a mixing assembly is arranged at a position below the blood measuring cartridge in the interior of the housing, wherein the mixing assembly is used to mix the liquid in the buffer cartridge, the antibody liquid cartridge and the blood measuring cartridge, and the mixing assembly comprises a mixing cartridge and a first motor. The device can first ionize impurities in a sample to improve the purity of the sample, thereby improving the accuracy of detection, and then use two sets of second electrode plates to detect the conductivity of a second nitrocellulose membrane to determine the concentration of anti-tumor drug metabolites in the blood, thereby achieving accurate detection, thereby facilitating medical personnel to use drugs of different dosages according to different patients.

Description

Technical Field

[0001] The present invention relates to the field of drug detection, and more specifically, to a device and method for detecting the concentration of anti-tumor drug metabolites in blood. Background Art

[0002] After a person takes a drug, the absorption, distribution, metabolism and excretion processes of the drug in the body vary greatly due to individual differences. Even if all patients receive the same dose of the drug, there may be significant differences in the blood drug concentrations of different people. This difference may even be as high as 3 to 10 times. In order to overcome the challenges brought about by such individual differences, it is particularly important to monitor drug concentrations.

[0003] Through precise drug concentration monitoring, doctors can gain an in-depth understanding of the drug metabolism characteristics of each patient, and thus adjust the dosing regimen according to the patient's specific situation to achieve truly individualized treatment. This approach not only ensures that the drug is maintained within a safe and effective concentration range in the patient's body, but also maximizes the efficacy of the drug while significantly reducing the risk of adverse reactions caused by overdose or underdose.

[0004] For anti-tumor drugs, due to their low therapeutic index and narrow safety range, the slightest carelessness in medication may lead to serious consequences such as insufficient dosage or overdose poisoning. By monitoring drug concentrations, chemotherapy toxicity and side effects (high blood drug concentrations) and auxiliary analysis of drug effectiveness (low blood drug concentrations) can be predicted, providing doctors with a basis for adjusting treatment plans. Therefore, monitoring of drug concentrations is particularly important in anti-tumor treatment. It can help doctors better understand the dynamic changes of drugs in the patient's body, ensure that the drugs can accurately and safely exert their therapeutic effects, and bring better treatment effects and quality of life to patients.

[0005] In the prior art, the detection of drug concentration in the patient's blood is generally carried out using a chromatograph. In actual use, the chromatograph needs to perform pre-treatment of the sample, such as extraction, evaporation, etc. The pre-treatment process is cumbersome and may affect the analysis results. In addition, the operation of the chromatograph is relatively complicated and requires professional personnel to operate and maintain it. In addition, the equipment cost and maintenance cost of the chromatograph are relatively high, which may pose a certain economic pressure on some small laboratories or enterprises. Summary of the invention

[0006] In view of the problems existing in the prior art, the purpose of the present invention is to provide a device and method for detecting the concentration of anti-tumor drug metabolites in blood, which can be achieved by injecting plasma, buffer solution and antibody solution into a mixing cylinder, and rotating the mixing cylinder to quickly mix the three to produce a precipitate, and then injecting the precipitate and liquid onto a first nitrocellulose membrane, and then the first electrode plate ionizes the antibody protein on the precipitate to remove impurities inside the precipitate, thereby ensuring the purity of the test sample, and then dripping a dissolving solution onto the precipitate to dissolve it, and the liquid after the solution flows downward to flow into the second nitrocellulose membrane, and the conductivity of the second nitrocellulose membrane is detected by two groups of second electrode plates to determine the concentration of the metabolites of the anti-tumor drug in the blood, thereby achieving accurate detection, thereby facilitating medical personnel to use different doses of drugs according to different patients.

[0007] To solve the above problems, the present invention adopts the following technical solutions.

[0008] A device for detecting the concentration of anti-tumor drug metabolites in blood, comprising a shell, a buffer cartridge is installed on the upper end surface of the shell, an antibody liquid cartridge is installed at a position close to the buffer cartridge on the upper surface of the shell, a blood measuring cartridge is installed at a position close to the buffer cartridge on the upper surface of the shell, a mixing assembly is arranged at a position below the blood measuring cartridge in the interior of the shell, the mixing assembly is used to mix the liquids in the buffer cartridge, the antibody liquid cartridge and the blood measuring cartridge, the mixing assembly comprises a mixing cartridge and a first motor, the interior of the mixing cartridge is respectively connected to the interiors of the buffer cartridge, the antibody liquid cartridge and the blood measuring cartridge, and the first motor is used to drive the mixing cartridge to rotate;

[0009] A removal component is also provided below the mixing component, and the removal component is used to remove impurities in the sample. The removal component includes a first nitrocellulose membrane and a first electrode plate. The first electrode plates are provided in two groups and are provided above the first nitrocellulose membrane. The two groups of the first electrode plates are used to ionize the antibody protein on the first nitrocellulose membrane.

[0010] A detection component is arranged below the impurity removal component, and the detection component is used to detect drug residues in the blood.

[0011] Further, the mixing assembly also includes a gear, the output shaft of the first motor is fixedly connected with a gear, the gear is meshedly connected with the side surface of the mixing cylinder, a first peristaltic pump is installed below the buffer cylinder, the liquid inlet of the first peristaltic pump is connected with the inside of the buffer cylinder, a first conduit is connected to the liquid outlet of the first peristaltic pump, and an end of the first conduit away from the first peristaltic pump is arranged above the mixing cylinder;

[0012] A second peristaltic pump is installed below the antibody liquid cylinder, the liquid inlet of the second peristaltic pump is interconnected with the interior of the antibody liquid cylinder, the liquid outlet of the second peristaltic pump is fixedly connected with a second conduit, and one end of the second conduit away from the second peristaltic pump is arranged above the mixing cylinder, and a third peristaltic pump is installed below the blood measuring cylinder, the oil inlet of the third peristaltic pump is interconnected with the interior of the blood measuring cylinder, the liquid outlet of the blood measuring cylinder is connected with a third conduit, and the lower end of the third conduit is arranged at the upper port of the mixing cylinder.

[0013] Furthermore, a fixed pipe is fixedly connected to the center of the lower end of the mixing cylinder, a discharge pipe is rotatably connected to the lower end of the fixed pipe, and a solenoid valve is installed on the discharge pipe;

[0014] The impurity removal component includes a first fixed frame, which is arranged below the discharge pipe, and a plurality of groups of evenly distributed first support plates are fixedly connected inside the first fixed frame, and the first nitrocellulose membrane contact is arranged above the first support plate.

[0015] Further, a dissolving liquid cartridge is installed on the upper surface of the shell near the buffer cartridge, a fourth peristaltic pump is installed below the dissolving liquid cartridge, a liquid inlet of the fourth peristaltic pump is communicated with the interior of the dissolving liquid cartridge, a fourth conduit is connected to the liquid outlet of the fourth peristaltic pump, an end of the fourth conduit away from the fourth peristaltic pump is connected to the side surface of the discharge pipe, and the interior of the fourth conduit is communicated with the interior of the discharge pipe;

[0016] The detection component includes a second nitrocellulose membrane and a second electrode plate, the second electrode plates are arranged in two groups, the two groups of second electrode plates are arranged above the second nitrocellulose membrane, the second electrode plate is used to detect the conductivity of the liquid inside the second nitrocellulose membrane, the detection component also includes a second fixed frame, the second fixed frame is arranged below the first fixed frame, multiple groups of second support plates are fixedly connected inside the second fixed frame, the second nitrocellulose membrane contact is arranged above the second support plate, and a waste liquid box is arranged below the second fixed frame.

[0017] Further, two groups of blocking plates are arranged between the two groups of the first electrode plates, a connecting plate is fixedly connected between the two groups of the blocking plates, a first permanent magnet is installed on the upper surface of the connecting plate, a first electromagnet is arranged directly above the first permanent magnet, a first support rod is installed on the side surface of the first electromagnet, and one end of the first support rod away from the first electromagnet is fixedly connected to the inner wall of the shell;

[0018] A first slide rail is provided at one end of the blocking plate away from the connecting plate, a slider is slidably provided inside the first slide rail, one side of the slider is fixedly connected to the corresponding blocking plate, a first spring is fixedly connected to the lower end of the slider, and the lower end of the first spring is fixedly connected to the inner wall of the first slide rail.

[0019] Furthermore, a first insulating plate is fixedly connected between the two groups of the first electrode plates, a second permanent magnet is installed inside the first insulating plate at a position directly above the first electromagnet, a second slide rail is provided at one end of the first electrode plate away from the first insulating plate, a first conductive block is slidably provided inside the second slide rail, the first conductive block is fixedly connected to the corresponding first electrode plate, a second spring is fixedly connected to the upper end of the first conductive block, and the upper end of the second spring is fixedly connected to the inner wall of the second slide rail.

[0020] Further, a second insulating plate is fixedly connected between the two groups of the second electrode plates, a third permanent magnet is fixedly connected to the upper surface of the second insulating plate, a second electromagnet is arranged directly above the third permanent magnet, a second connecting rod is fixedly connected to the side surface of the second electromagnet, and an end of the second connecting rod away from the second electromagnet is fixedly connected to the inner wall of the shell;

[0021] A third slide rail is arranged at one end of the second electrode plate away from the second insulating plate, a second conductive block is slidably arranged inside the third slide rail, a third spring is fixedly connected to the lower end of the second conductive block, and the lower end of the third spring is fixedly connected to the inner wall of the third slide rail.

[0022] Furthermore, a diverter box is fixedly connected to the lower end of the discharge pipe, and a plurality of evenly distributed drainage holes are provided on the lower end surface of the diverter box.

[0023] Furthermore, the lower ends of the first fixed frame and the second fixed frame are slidably connected to support bars, and the support bars are fixedly connected to the inner wall of the shell. The first fixed frame and the second fixed frame are threadedly connected to screw rods, and the right end of the screw rods is fixedly connected to the second motor. A through hole is opened on the left side wall of the shell at the position corresponding to the first fixed frame and the second fixed frame.

[0024] The present invention also provides a method for detecting the concentration of anti-tumor drug metabolites in blood applicable to the above-mentioned device for detecting the concentration of anti-tumor drug metabolites in blood, comprising the following steps:

[0025] S1: Mixing liquid: Plasma, buffer and antibody solution are injected into the mixing cylinder, and the mixing cylinder is rotated to quickly mix the three to produce a precipitate, and the precipitate and liquid are injected onto the first nitrocellulose membrane for impurity removal;

[0026] S2: Removing impurities: The electrodes at both ends of the first electrode plate are different to ionize the precipitate on the first nitrocellulose membrane. The antibody protein on the precipitate is negatively charged, and the antibody protein will be freed toward the anode of the first electrode plate, thereby removing impurities inside the precipitate;

[0027] S3: Detect sample: add dissolving solution to the precipitate to dissolve it. The liquid after solution flows downward and flows into the second nitrocellulose membrane. The conductivity of the second nitrocellulose membrane is detected by two sets of second electrode plates to determine the concentration of metabolites of anti-tumor drugs in the blood.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] This solution injects plasma, buffer solution and antibody solution into a mixing cylinder, rotates the mixing cylinder, and quickly mixes the three to produce a precipitate. The precipitate and liquid are then injected onto a first nitrocellulose membrane, and the first electrode plate ionizes the antibody protein on the precipitate to remove impurities inside the precipitate, thereby ensuring the purity of the test sample. A dissolving solution is then dripped onto the precipitate to dissolve it, and the liquid after the solution flows downward to flow into the second nitrocellulose membrane. The conductivity of the second nitrocellulose membrane is detected by two sets of second electrode plates to determine the concentration of the metabolites of the anti-tumor drug in the blood, thereby achieving accurate detection, thereby facilitating medical personnel to use different doses of drugs according to different patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is an appearance view of the overall structure of the present invention;

[0031] Figure 2 It is a structural view of the interior of the housing of the present invention;

[0032] Figure 3 A structural view of the mixing assembly of the present invention;

[0033] Figure 4 For the present invention Figure 2 A magnified view of point A in the middle;

[0034] Figure 5 A structural view of the impurity removal component of the present invention;

[0035] Figure 6 It is a schematic diagram of the separation of the first fixing frame and the first nitrocellulose membrane of the present invention;

[0036] Figure 7 This is a disassembled view of the impurity removal component of the present invention;

[0037] Figure 8 For the present invention Figure 7 A magnified view of point B in the middle;

[0038] Fig. 9 It is a structural view of the detection component of the present invention;

[0039] Fig.10 It is a schematic diagram of the splitting of the detection component of the present invention;

[0040] Fig.11 This is a diagram showing the interior of the third slide rail of the present invention.

[0041] Description of the numbers in the figure:

[0042] 1. Shell; 2. Buffer cartridge; 3. Antibody cartridge; 4. First peristaltic pump; 5. Second peristaltic pump; 6. First catheter; 7. Second catheter; 8. Blood test cartridge; 9. Third peristaltic pump; 10. Mixing cartridge; 11. First motor; 12. Gear; 13. Fixed tube; 14. Discharge tube; 15. Solenoid valve; 16. Diverter box; 17. Drain hole; 18. First fixed frame; 19. First support plate; 20. First nitrocellulose membrane; 22. First electrode plate; 23. Second permanent magnet; 24. First insulating plate; 25. First conductive block; 26. Second spring; 27. Second slide rail; 28. First electromagnet; 29. ​​First Support rod; 30, connecting plate; 31, blocking plate; 32, sliding block; 33, first slide rail; 34, first spring; 35, dissolving liquid cylinder; 36, fourth peristaltic pump; 37, fourth conduit; 38, second fixing frame; 39, second support plate; 40, second nitrocellulose membrane; 42, second insulating plate; 43, third permanent magnet; 44, second electromagnet; 45, second connecting rod; 46, second electrode plate; 47, second conductive block; 48, third slide rail; 49, third spring; 50, second motor; 51, screw rod; 52, supporting bar; 53, through hole; 54, waste liquid box; 55, third conduit; 56, first permanent magnet. DETAILED DESCRIPTION

[0043] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention; it is obvious that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments, and all other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making creative work are within the scope of protection of the present invention.

[0044] See also Figures 1 to 3, a device for detecting the concentration of anti-tumor drug metabolites in blood, comprising a shell 1, a buffer cartridge 2 is mounted on the upper end surface of the shell 1, an antibody liquid cartridge 3 is mounted on the upper surface of the shell 1 near the buffer cartridge 2, a blood measuring cartridge 8 is mounted on the upper surface of the shell 1 near the buffer cartridge 2, a mixing assembly is arranged at a position below the blood measuring cartridge 8 inside the shell 1, the mixing assembly is used to mix the liquids in the buffer cartridge 2, the antibody liquid cartridge 3 and the blood measuring cartridge 8, the mixing assembly comprises a mixing cartridge 10 and a first motor 11, the interior of the mixing cartridge 10 is respectively connected with the interiors of the buffer cartridge 2, the antibody liquid cartridge 3 and the blood measuring cartridge 8, and the first motor 11 is used to drive the mixing cartridge 10 to rotate;

[0045] The mixing assembly further includes a gear 12, the output shaft of the first motor 11 is fixedly connected with the gear 12, the gear 12 is meshedly connected with the side surface of the mixing barrel 10, a first peristaltic pump 4 is installed below the buffer barrel 2, the liquid inlet of the first peristaltic pump 4 is communicated with the inside of the buffer barrel 2, a first conduit 6 is connected to the liquid outlet of the first peristaltic pump 4, and one end of the first conduit 6 away from the first peristaltic pump 4 is arranged above the mixing barrel 10;

[0046] A second peristaltic pump 5 is installed below the antibody liquid cylinder 3, and the liquid inlet of the second peristaltic pump 5 is interconnected with the interior of the antibody liquid cylinder 3, and the liquid outlet of the second peristaltic pump 5 is fixedly connected with a second conduit 7, and one end of the second conduit 7 away from the second peristaltic pump 5 is arranged above the mixing cylinder 10, and a third peristaltic pump 9 is installed below the blood measuring cylinder 8, and the oil inlet of the third peristaltic pump 9 is interconnected with the interior of the blood measuring cylinder 8, and the liquid outlet of the blood measuring cylinder 8 is connected with a third conduit 55, and the lower end of the third conduit 55 is arranged at the upper port of the mixing cylinder 10.

[0047] During the test, firstly, an appropriate amount of blood is drawn from the patient, and then the blood is separated to obtain plasma or serum, which can eliminate the interference of cell components such as red blood cells, white blood cells and platelets in the blood on the determination of drug concentration, and improve the accuracy and reliability of the test. Plasma is the liquid part of the blood after the cell components are removed, and contains drugs and their metabolites. The result obtained by testing plasma is more accurate. The staff opens the sealing cover on the blood measuring cylinder 8, drips an appropriate amount of plasma into the interior of the blood measuring cylinder 8, and then turns on the second peristaltic pump 5. The antibody liquid is contained in the antibody liquid cylinder 3. The antibody liquid is extracted by the second peristaltic pump 5, and the antibody liquid is injected into the mixing cylinder 10 through the second conduit 7. The third peristaltic pump 9 extracts blood in the blood measuring cylinder 8. The plasma is injected into the mixing barrel 10 through the third conduit 55. The anti-tumor drug metabolites in the plasma will undergo a specific immune reaction with the antibody liquid to generate a precipitate. The precipitate is a complex of the antibody and the drug. The gear 12 is driven by the first motor 11, and the mixing barrel 10 is driven to rotate by the gear 12, which helps to fully mix the plasma and the antibody liquid. Then the first peristaltic pump 4 extracts the buffer in the buffer cartridge 2 and injects it into the mixing barrel 10 through the first conduit 6. The buffer is used to provide an electrophoretic environment for the precipitate. In addition, the antibody protein in the antibody liquid is linked to an electronegative group that can improve the conductivity of the buffer. Then, by rotating the mixing barrel 10, the buffer is fully mixed with the liquid in the mixing barrel 10.

[0048] like Figures 4 to 8 As shown, a removal component is also provided below the mixing component, and the removal component is used to remove impurities in the sample. The removal component includes a first nitrocellulose membrane 20 and a first electrode plate 22. The first electrode plate 22 is provided in two groups and is provided above the first nitrocellulose membrane 20. The two groups of first electrode plates 22 are used to ionize the antibody protein on the first nitrocellulose membrane 20.

[0049] A fixed pipe 13 is fixedly connected to the center of the lower end of the mixing cylinder 10, and a discharge pipe 14 is rotatably connected to the lower end of the fixed pipe 13. A solenoid valve 15 is installed on the discharge pipe 14, and a diverter box 16 is fixedly connected to the lower end of the discharge pipe 14. The lower end surface of the diverter box 16 is provided with multiple groups of evenly distributed drainage holes 17;

[0050] The impurity removal component includes a first fixed frame 18, which is arranged below the discharge pipe 14, and a plurality of groups of evenly distributed first support plates 19 are fixedly connected inside the first fixed frame 18, and a first nitrocellulose membrane 20 is arranged above the first support plate 19 in contact with the first support plate 19;

[0051] A first insulating plate 24 is fixedly connected between the two groups of first electrode plates 22, a second permanent magnet 23 is mounted on the first insulating plate 24, a first electromagnet 28 is arranged directly below the second permanent magnet 23, a second slide rail 27 is arranged at one end of the first electrode plate 22 away from the first insulating plate 24, a first conductive block 25 is slidably arranged inside the second slide rail 27, the first conductive block 25 is fixedly connected to the corresponding first electrode plate 22, a second spring 26 is fixedly connected to the upper end of the first conductive block 25, and the upper end of the second spring 26 is fixedly connected to the inner wall of the second slide rail 27.

[0052] After the mixing is completed, the solenoid valve 15 is driven to open the discharge pipe 14, and the liquid and sediment in the mixing barrel 10 will flow downward along the discharge pipe 14, and finally flow into the diversion box 16, flow out through the drainage hole 17, and flow into the first nitrocellulose membrane 20. The liquid will penetrate the first nitrocellulose membrane 20 and flow downward through the intervals inside the first nitrocellulose membrane 20. The solid sediment remains on the first nitrocellulose membrane 20, and the first electromagnet 28 is controlled to be energized. At this time, the upper magnetic pole of the first electromagnet 28 is different from the lower magnetic pole of the second permanent magnet 23. The first electromagnet 28 will attract the second permanent magnet 23, thereby driving the first insulating plate 24 to move downward. When the first insulating plate 24 moves downward It will drive the two groups of first electrode plates 22 to move downward, and finally the first electrode plates 22 will be against the first nitrocellulose membrane 20. When the first electrode plate 22 moves downward, it will drive the first conductive block 25 to pull the second spring 26 downward. The second slide rail 27 is made of conductive material, such as metal copper, metal zinc, etc. When the two groups of second slide rails 27 are powered on, the current will flow to the first electrode plate 22 through the first conductive block 25, and the impurities on the precipitate will be ionized through the two groups of first electrode plates 22. Since the free antibodies are electronegative, they gradually gather toward the positive end of the first electrode plate 22 during the ionization process, so that the free antibody proteins around the precipitate are removed, thereby removing the impurities on the precipitate, thereby improving the purity of the test sample.

[0053] like Figures 9 to 11 As shown, the detection component includes a second fixed frame 38, which is arranged at a lower position of the first fixed frame 18, and a plurality of second support plates 39 are fixedly connected inside the second fixed frame 38. The second nitrocellulose membrane 40 is contact-arranged above the second support plate 39, and a waste liquid box 54 is arranged below the second fixed frame 38.

[0054] A second insulating plate 42 is fixedly connected between the two groups of second electrode plates 46, a third permanent magnet 43 is fixedly connected to the upper surface of the second insulating plate 42, a second electromagnet 44 is arranged directly above the third permanent magnet 43, a second connecting rod 45 is fixedly connected to the side surface of the second electromagnet 44, and one end of the second connecting rod 45 away from the second electromagnet 44 is fixedly connected to the inner wall of the housing 1;

[0055] A third slide rail 48 is provided at one end of the second electrode plate 46 away from the second insulating plate 42, a second conductive block 47 is slidably provided inside the third slide rail 48, a third spring 49 is fixedly connected to the lower end of the second conductive block 47, and the lower end of the third spring 49 is fixedly connected to the inner wall of the third slide rail 48.

[0056] After the antibody protein impurities on the precipitate are removed, the fourth peristaltic pump 36 is turned on, the fourth peristaltic pump 36 extracts the dissolving liquid in the dissolving liquid cylinder 35, and transports it to the discharge pipe 14 through the fourth conduit 37. The dissolving liquid flows into the diversion box 16 along the discharge pipe 14, and finally flows out from the drainage hole 17 and flows into the precipitate. The dissolving liquid will gradually dissolve the precipitate, and the dissolved precipitate will pass through the first nitrocellulose membrane 20 and drip onto the second nitrocellulose membrane 40. The excess liquid on the second nitrocellulose membrane 40 will pass through the second nitrocellulose membrane 40 and flow into the waste liquid box 54. After the precipitate is dissolved, the second electromagnet 44 is turned on, and the lower end of the second electromagnet 44 The generated magnetic poles are the same as the magnetic poles at the upper end of the third permanent magnet 43. The magnetic repulsion of the second electromagnet 44 pushes the third permanent magnet 43 to move downward. When the third permanent magnet 43 moves downward, it will drive the second insulating plate 42 and the second electrode plate 46 to move downward together. Finally, the lower end of the second electrode plate 46 contacts the second nitrocellulose membrane 40. The third slide rail 48 is made of conductive material. By detecting the conductivity between the two groups of third slide rails 48, that is, detecting the conductivity between the two groups of second electrode plates 46, the concentration of the metabolites of the anti-tumor drug in the blood is determined by the size of the conductivity, thereby achieving accurate detection, thereby facilitating medical personnel to use different doses of drugs according to different patients.

[0057] like Figure 2 , Figures 4 to 8 As shown, two groups of blocking plates 31 are arranged between the two groups of first electrode plates 22, a connecting plate 30 is fixedly connected between the two groups of blocking plates 31, a first permanent magnet 56 is installed on the upper surface of the connecting plate 30, a first electromagnet 28 is arranged directly above the first permanent magnet 56, a first support rod 29 is installed on the side surface of the first electromagnet 28, and one end of the first support rod 29 away from the first electromagnet 28 is fixedly connected to the inner wall of the housing 1;

[0058] A first slide rail 33 is provided at one end of the blocking plate 31 away from the connecting plate 30, and a slider 32 is slidably provided inside the first slide rail 33. One side of the slider 32 is fixedly connected to the corresponding blocking plate 31, and a first spring 34 is fixedly connected to the lower end of the slider 32. The lower end of the first spring 34 is fixedly connected to the inner wall of the first slide rail 33.

[0059] A dissolving liquid cartridge 35 is installed on the upper surface of the shell 1 near the buffer cartridge 2, and a fourth peristaltic pump 36 is installed below the dissolving liquid cartridge 35. The liquid inlet of the fourth peristaltic pump 36 is interconnected with the interior of the dissolving liquid cartridge 35, and a fourth conduit 37 is connected to the liquid outlet of the fourth peristaltic pump 36. One end of the fourth conduit 37 away from the fourth peristaltic pump 36 is connected to the side surface of the discharge pipe 14, and the interior of the fourth conduit 37 is interconnected with the interior of the discharge pipe 14.

[0060] When the dissolving liquid drops on the first nitrocellulose membrane 20 to dissolve the precipitate, it is easy to be stained with the antibody protein on the anode of the first electrode plate 22, causing the detected sample to be contaminated by impurities again. For this reason, the present invention changes the direction of the current inside the first electromagnet 28 when dissolving the precipitate. At this time, the magnetic poles at the upper and lower ends of the first electromagnet 28 change. The upper magnetic pole of the first electromagnet 28 is the same as the magnetic pole of the upper end of the second permanent magnet 23. The first electromagnet 28 pushes the second permanent magnet 23 upward through magnetic repulsion. Finally, the first electrode plate 22 leaves the first nitrocellulose membrane 20. At this time, the lower magnetic pole of the first electromagnet 28 is the same as the magnetic pole of the upper end of the first permanent magnet 56. The first electromagnet 28 moves the first permanent magnet 56 downward through magnetic repulsion. At the same time, the connecting plate 30 and the blocking plate 31 move downward. The blocking plate 31 presses the first nitrocellulose membrane 20. When the dissolving liquid dissolves the precipitate, the antibody protein at the end of the first nitrocellulose membrane 20 is prevented from contacting the dissolving liquid, thereby ensuring the purity of the detected sample and thus ensuring the accuracy of the test result.

[0061] like Figure 2 , Figure 4 , Figure 5 and Fig. 9 As shown, the lower ends of the first fixed frame 18 and the second fixed frame 38 are slidably connected with a support bar 52, and the support bar 52 is fixedly connected to the inner wall of the shell 1. The first fixed frame 18 and the second fixed frame 38 are threadedly connected with a screw rod 51, and the right end of the screw rod 51 is fixedly connected to the second motor 50. A through hole 53 is opened on the left side wall of the shell 1 at the position corresponding to the first fixed frame 18 and the second fixed frame 38.

[0062] After the detection is completed, the second motor 50 is turned on to drive the screw rod 51 to rotate. The screw rod 51 rotates to drive the first fixed frame 18 and the second fixed frame 38 to move to the left, and finally move out of the through hole 53. At this time, the first nitrocellulose membrane 20 and the second nitrocellulose membrane 40 are removed and thrown into the medical waste bin. When the first fixed frame 18 and the second fixed frame 38 are driven back to the initial position, when the equipment needs to be cleaned, a cleaning liquid is injected into the blood measuring cylinder 8, and the cleaning liquid flows downward into the mixing cylinder 10. The mixing cylinder 10 is driven to rotate by the first motor 11, and the mixing cylinder 10 rotates to make the cleaning liquid contact with the inner wall of the mixing cylinder 10, and finally the cleaning liquid is discharged. Finally, the cleaning liquid flows into the waste liquid box 54. The cleaning liquid will clean the pipeline passing through during the downward flow, and the cleaned equipment is ready for next use.

[0063] The present invention also provides a method for detecting the concentration of anti-tumor drug metabolites in blood applicable to the above-mentioned device for detecting the concentration of anti-tumor drug metabolites in blood, comprising the following steps:

[0064] S1: Mixing liquid: Plasma, buffer solution and antibody solution are injected into the mixing cylinder 10, and the mixing cylinder 10 is rotated to quickly mix the three to produce a precipitate, and the precipitate and liquid are injected onto the first nitrocellulose membrane 20 for impurity removal;

[0065] S2: Removing impurities: The electrodes at both ends of the first electrode plate 22 are different to ionize the precipitate on the first nitrocellulose membrane 20. The antibody protein on the precipitate is negatively charged and will be freed toward the anode of the first electrode plate 22, thereby removing impurities inside the precipitate;

[0066] S3: Detecting samples: Add dissolving liquid to the precipitate to dissolve it. The liquid after solution flows downward and flows into the second nitrocellulose membrane 40. The conductivity of the second nitrocellulose membrane 40 is detected by two sets of second electrode plates 46 to determine the concentration of the metabolites of the anti-tumor drug in the blood.

[0067] The above is only a preferred specific implementation of the present invention; however, the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical solution and its improved conception within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A device for detecting the concentration of anti-tumor drug metabolites in blood, comprising a housing (1), characterized in that: A buffer cartridge (2) is mounted on the upper end surface of the shell (1); an antibody liquid cartridge (3) is mounted on the upper surface of the shell (1) at a position close to the buffer cartridge (2); a blood measuring cartridge (8) is mounted on the upper surface of the shell (1) at a position close to the buffer cartridge (2); a mixing assembly is arranged inside the shell (1) at a position below the blood measuring cartridge (8); the mixing assembly is used to mix the liquids in the buffer cartridge (2), the antibody liquid cartridge (3) and the blood measuring cartridge (8); the mixing assembly comprises a mixing cartridge (10) and a first motor (11); the interior of the mixing cartridge (10) is respectively connected to the interiors of the buffer cartridge (2), the antibody liquid cartridge (3) and the blood measuring cartridge (8); the first motor (11) is used to drive the mixing cartridge (10) to rotate; A de-impurity component is also provided below the mixing component, and the de-impurity component is used to remove impurities in the sample. The de-impurity component comprises a first nitrocellulose membrane (20) and a first electrode plate (22). The first electrode plate (22) is provided in two groups and is provided above the first nitrocellulose membrane (20). The two groups of the first electrode plates (22) are used to ionize the antibody protein on the first nitrocellulose membrane (20); A detection component is disposed below the impurity removal component, and the detection component is used to detect drug residues in the blood; The mixing assembly further comprises a gear (12), the gear (12) being fixedly connected to the output shaft of the first motor (11), the gear (12) being meshingly connected to the side surface of the mixing barrel (10), a first peristaltic pump (4) being installed below the buffer barrel (2), the liquid inlet of the first peristaltic pump (4) being interconnected with the interior of the buffer barrel (2), a first conduit (6) being connected to the liquid outlet of the first peristaltic pump (4), and an end of the first conduit (6) away from the first peristaltic pump (4) being arranged above the mixing barrel (10); A second peristaltic pump (5) is installed below the antibody liquid cylinder (3), the liquid inlet of the second peristaltic pump (5) is interconnected with the interior of the antibody liquid cylinder (3), the liquid outlet of the second peristaltic pump (5) is fixedly connected with a second conduit (7), one end of the second conduit (7) away from the second peristaltic pump (5) is arranged above the mixing cylinder (10), a third peristaltic pump (9) is installed below the blood measuring cylinder (8), the oil inlet of the third peristaltic pump (9) is interconnected with the interior of the blood measuring cylinder (8), the liquid outlet of the blood measuring cylinder (8) is connected with a third conduit (55), and the lower end of the third conduit (55) is arranged at the upper end of the mixing cylinder (10); A fixed pipe (13) is fixedly connected at the center of the lower end of the mixing cylinder (10), a discharge pipe (14) is rotatably connected to the lower end of the fixed pipe (13), and a solenoid valve (15) is installed on the discharge pipe (14); The impurity removal component comprises a first fixed frame (18), the first fixed frame (18) being arranged at a position below the discharge pipe (14), a plurality of groups of evenly distributed first support plates (19) being fixedly connected inside the first fixed frame (18), and the first nitrocellulose membrane (20) being arranged in contact with a position above the first support plate (19); A dissolving liquid cartridge (35) is installed on the upper surface of the shell (1) at a position close to the buffer cartridge (2), and a fourth peristaltic pump (36) is installed below the dissolving liquid cartridge (35); the liquid inlet of the fourth peristaltic pump (36) is connected to the interior of the dissolving liquid cartridge (35), and the liquid outlet of the fourth peristaltic pump (36) is connected to a fourth conduit (37), and one end of the fourth conduit (37) away from the fourth peristaltic pump (36) is connected to the side surface of the discharge pipe (14), and the interior of the fourth conduit (37) is connected to the interior of the discharge pipe (14); The detection component comprises a second nitrocellulose membrane (40) and a second electrode plate (46), wherein the second electrode plate (46) is provided in two groups, wherein the two groups of the second electrode plates (46) are provided above the second nitrocellulose membrane (40), and the second electrode plates (46) are used to detect the conductivity of the liquid inside the second nitrocellulose membrane (40). The detection component also comprises a second fixing frame (38), wherein the second fixing frame (38) is provided below the first fixing frame (18), wherein the interior of the second fixing frame (38) is fixedly connected with a plurality of groups of second support plates (39), wherein the second nitrocellulose membrane (40) is contacted and provided above the second support plates (39), and a waste liquid box (54) is provided below the second fixing frame (38); Two groups of baffle plates (31) are arranged between the two groups of the first electrode plates (22); a connecting plate (30) is fixedly connected between the two groups of the baffle plates (31); a first permanent magnet (56) is mounted on the upper surface of the connecting plate (30); a first electromagnet (28) is arranged directly above the first permanent magnet (56); a first support rod (29) is mounted on the side surface of the first electromagnet (28); and an end of the first support rod (29) away from the first electromagnet (28) is fixedly connected to the inner wall of the housing (1); A first slide rail (33) is disposed at one end of the blocking plate (31) away from the connecting plate (30); a slider (32) is slidably disposed inside the first slide rail (33); a side surface of the slider (32) is fixedly connected to the corresponding blocking plate (31); a first spring (34) is fixedly connected to the lower end of the slider (32); and the lower end of the first spring (34) is fixedly connected to the inner wall of the first slide rail (33); A first insulating plate (24) is fixedly connected between the two groups of the first electrode plates (22); a second permanent magnet (23) is installed inside the first insulating plate (24) at a position directly above the first electromagnet (28); a second slide rail (27) is provided at one end of the first electrode plate (22) away from the first insulating plate (24); a first conductive block (25) is slidably provided inside the second slide rail (27); the first conductive block (25) is fixedly connected to the corresponding first electrode plate (22); a second spring (26) is fixedly connected to the upper end of the first conductive block (25); and the upper end of the second spring (26) is fixedly connected to the inner wall of the second slide rail (27); A second insulating plate (42) is fixedly connected between the two groups of the second electrode plates (46); a third permanent magnet (43) is fixedly connected to the upper surface of the second insulating plate (42); a second electromagnet (44) is arranged directly above the third permanent magnet (43); a second connecting rod (45) is fixedly connected to the side surface of the second electromagnet (44); and an end of the second connecting rod (45) away from the second electromagnet (44) is fixedly connected to the inner wall of the housing (1); A third slide rail (48) is provided at one end of the second electrode plate (46) away from the second insulating plate (42); a second conductive block (47) is slidably provided inside the third slide rail (48); a third spring (49) is fixedly connected to the lower end of the second conductive block (47); and the lower end of the third spring (49) is fixedly connected to the inner wall of the third slide rail (48); The lower end of the discharge pipe (14) is fixedly connected to a diverter box (16), and the lower end surface of the diverter box (16) is provided with a plurality of groups of evenly distributed liquid discharge holes (17).

2. The device for detecting the concentration of anti-tumor drug metabolites in blood according to claim 1, characterized in that: The lower ends of the first fixed frame (18) and the second fixed frame (38) are slidably connected to support bars (52), and the support bars (52) are fixedly connected to the inner wall of the shell (1). The first fixed frame (18) and the second fixed frame (38) are threadedly connected to screw rods (51), and the right end of the screw rod (51) is fixedly connected to the second motor (50). A through hole (53) is provided on the left side wall of the shell (1) at a position corresponding to the first fixed frame (18) and the second fixed frame (38).

3. A method for detecting the concentration of anti-tumor drug metabolites in blood applicable to the device for detecting the concentration of anti-tumor drug metabolites in blood according to any one of claims 1 to 2, characterized in that: The steps include: S1: Mixing liquid: Plasma, buffer solution and antibody solution are injected into the mixing cylinder (10), and the mixing cylinder (10) is rotated to allow the three to mix quickly to produce a precipitate, and the precipitate and liquid are injected onto the first nitrocellulose membrane (20) for use in removing impurities; S2: removing impurities: the electrodes at both ends of the first electrode plate (22) are different to ionize the precipitate on the first nitrocellulose membrane (20). The antibody protein on the precipitate is negatively charged and will be freed toward the anode of the first electrode plate (22), thereby removing impurities inside the precipitate; S3: Detecting samples: Add a dissolving solution to the precipitate to dissolve it. The liquid after the solution flows downward and flows into the second nitrocellulose membrane (40). The conductivity of the second nitrocellulose membrane (40) is detected by two sets of second electrode plates (46) to determine the concentration of the metabolites of the anti-tumor drug in the blood.

Images